Yes!
We can end TB
GC7 Allocations & Application windows
GC7 Allocations by disease

- With the slightly higher resource envelope and the new global disease split, the amounts of funding allocated for 2023-2025 compared to 2020-2022 are:
  - $152.6 million for HIV
  - **$154.2 million more for TB**
  - $111.2 million more for malaria

- An additional **US$ 82 million in Catalytic Funding (Matching Funds)** has been allocated to select countries to “Find and successfully treat the missing people with drug-susceptible TB and drug-resistant TB.”
Allocations to 20 GF TB Priority countries

- The top 20 TB priority countries have aggregate allocations of over US$1.7 billion in GC7.

- This corresponds to an increase of 8.4% and represents 71% of total TB funding.

- 16 out of the 20 priority countries have an increased allocation in GC7.
Approximately 136 allocation applications are expected in 2023. The first applications for GC7 are expected later this month.

Over 50% of funding applications are expected in window 2 (May 2023).

Continued partner support will be critical for the smooth review of good quality requests for funding.

Data as of 10 March 2023
## TB Program Essentials: Improving quality and innovations:

| 1. TB Screening & Diagnosis | • Systematic screening using CXR +/- CAD  
|                           | • Rapid molecular assays as first diagnostic test  
|                           | • Testing for at least rifampicin resistance in bacteriologically confirmed TB  
<table>
<thead>
<tr>
<th></th>
<th>• Efficient TB diagnostic networks</th>
</tr>
</thead>
</table>
| 2. TB Treatment & Care    | • Child friendly formulations, 4-month regimen for non-severe DS-TB in children  
|                           | • Shorter all-oral regimens for DR-TB  
<table>
<thead>
<tr>
<th></th>
<th>• People-centered support for treatment completion</th>
</tr>
</thead>
</table>
| 3. TB Prevention          | • TB Preventive Therapy available for all eligible people: PLHIV, children, eligible household contacts of people with bacteriologically confirmed TB.  
<table>
<thead>
<tr>
<th></th>
<th>• Shorter TB Preventive Therapy regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. TB/HIV Collaborative Activities</td>
<td>• All PLHIV with active TB started on ART early as per recommendations</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------------------------</td>
</tr>
</tbody>
</table>
| 5. Cross-cutting areas    | • Real-time digital case-based TB surveillance  
|                           | • Private sector engagement  
|                           | • Decentralized, community & home-based people centered services  
|                           | • Human rights & gender-responsive programming |
Portfolio Financial Absorption
In-country absorption for 5th replenishment IPs: IPs across all grant components achieved >80% absorption.

Evolution of In-Country Absorption for 5th replenishment IPs

In-country absorption vs % of IP elapsed

- **HIV/AIDS**
- **HIV/TB**
- **Tuberculosis**
- **Malaria**
- **Total portfolio**

*Excludes RSSH and Multi-Component (Z) grants. Figures are excluding COVID-19 funds*

**Grant component**

- HIV/AIDS
- HIV/TB
- Tuberculosis
- Malaria
- Total portfolio

**Total portfolio in-country absorption:** 84%

<table>
<thead>
<tr>
<th>% of IP time elapsed</th>
<th>In-country absorption</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-17%</td>
<td>Typically June of Year 1 of implementation</td>
</tr>
<tr>
<td>18-33%</td>
<td>Typically December of Year 1 of implementation</td>
</tr>
<tr>
<td>34-50%</td>
<td>Typically June of Year 2 of implementation</td>
</tr>
<tr>
<td>51-67%</td>
<td>Typically December of Year 2 of implementation</td>
</tr>
<tr>
<td>68-83%</td>
<td>Typically June of Year 3 of implementation</td>
</tr>
<tr>
<td>84-100%</td>
<td>Typically December of Year 3 of implementation</td>
</tr>
</tbody>
</table>

Data source: GOS extract (as of 09-Nov-2022).
Notes: Expenditure data as reported in GOS and reflecting the current status of Global Fund PU and PUDR validation and LFA verification.
Analysis by DASH team.
Latest in-country absorption for TB IPs:
TB IPs in the 6th replenishment are absorbing funds at a lower rate than the overall portfolio and also absorbing less than they were in the 5th replenishment.

Data source: GOS extract (as of 09-Nov-2022).
Notes: Expenditure data as reported in GOS and reflecting the current status of Global Fund PU and PUDR validation and LFA verification.
Analysis by DASH team.
COVID-19 Response Mechanism & Pandemic Preparedness
C19RM 2021 Investments in Mitigation
A total of US$176M was invested in TB Mitigation under C19RM 2021

- Of the US$3,456 million awarded (including recommendations for Board approval), **US$411 million (12%)** is invested in mitigating the impact of COVID-19 on HIV, TB and malaria programs.

- A total of **US$176M (42%)** of C19RM was invested in TB Mitigation.

- Countries have shown increased demand for digital chest X-rays, and multi-diseases platforms, including True Nat which are not only critical for TB but important for systems strengthening.

C19RM 2021 Awards in Mitigation

- **$105 (25%)** for HIV/AIDS
- **$176 (43%)** for TB
- **$131 (32%)** for malaria

(as of 30 November 2022)
An analysis on direct & indirect TB investments under C19RM was conducted in the 20 priority countries in 2022.

The analysis found that $97M was invested directly for TB mitigation and an additional $67M (42%) could be found in other COVID-19 modules including case management, Infection Prevention & Control and lab strengthening.

TB needs to remain a priority for the C19RM and shifts to Pandemic Preparedness due to the fact TB was heavily impacted, kills more than other diseases and infrastructure for TB will be key for the next pandemic.
C19RM Portfolio Optimization Wave 1: TB Mitigation

- A total of **US$133 million** has been awarded to TB Mitigation. Requests for integrated screening and testing are submitted under the TB mitigation category while contributing to strengthening multi-disease lab systems and diagnostics networks.

- **Drill down of investments in TB mitigation of US$133 million composed by:**
  - **US$54 million** (41%) for Digital X-rays
  - **US$33 million** (25%) for testing machines (GeneXpert & TrueNat), both contributing to integrated multi-disease diagnostic platforms.
  - **US$46 million** (34%) is targeted to TB testing consumables and other supporting investments.

C19RM Portfolio Optimization Awards in TB Mitigation (US$ million)

*Other TB investments include Mobile Testing Vans, mounted X-ray machines and campaign costs.*
Thank you!